Sperm cryopreservation of male cancer patients for fertility preservation: 10-year monocentric experience

Xiao Liu (liuxiaozhangjun@163.com)
Sichuan University WCSUH: Sichuan University West China Second University Hospital
https://orcid.org/0000-0001-8718-206X

Bo Liu
Sichuan University WCSUH: Sichuan University West China Second University Hospital

shasha liu
Sichuan University WCSUH: Sichuan University West China Second University Hospital

yang xian
Sichuan University WCSUH: Sichuan University West China Second University Hospital

wenrui zhao
Sichuan University WCSUH: Sichuan University West China Second University Hospital

bin zhou
Sichuan University WCSUH: Sichuan University West China Second University Hospital

xiao xiao
Sichuan University WCSUH: Sichuan University West China Second University Hospital

xiao fang zhu
Sichuan University WCSUH: Sichuan University West China Second University Hospital

li wang
Sichuan University WCSUH: Sichuan University West China Second University Hospital

min jiang
Sichuan University WCSUH: Sichuan University West China Second University Hospital

fuping li
Sichuan University WCSUH: Sichuan University West China Second University Hospital

Research Article

Keywords: sperm cryopreservation, male infertility, oncology, semen quality, assisted reproductive technologies

DOI: https://doi.org/10.21203/rs.3.rs-212790/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Semen cryopreservation is an effective method to preserve fertility, which is very important for male cancer patients. Unfortunately, due to unaware of the opportunities for sperm cryopreservation for both physicians and cancer patients, not a lot of data on evaluating the semen parameters and dispositions of the cryopreserved samples of Chinese cancer population are available in the literature.

**Methods:** We retrospectively reviewed semen parameters as well as the clinical outcomes of assisted reproductive treatments (ART) of 339 male cancer patients of Chinese population who were referred to our center from 2010 to 2019 for fertility preservation.

**Results:** We first classify the male tumors into six major types according to body regions. The most prevalent cancer patients who came from our cohort for sperm banking were hematological neoplasms patients, and the second cancers were germ cell tumors. Patients with germ cell tumors had the lowest pre-thaw and post-thaw concentration among the six major cancer types. However, we separately compared among testicular tumors, lymphoma and leukemia, it turned out that leukemia had the lowest pre-thaw concentration. Most cancer patients (58%) chose to go on keeping their specimens in storage. The second proportion selected to discard their specimens electively (31%). Over the years, there were only 13 patients (4%) returned to use their sperm by ART. In the storage samples, germ cell tumors were the most proportion ones (29.3%). Moreover, in the unfrozen samples, the percentage of hematological neoplasms were the most (45.5%).

**Conclusions:** To our knowledge, we had owned the most numbers of male cancers who came to sperm bank for fertility conservation in the southwest of China. In our study we suggested that sperm quality could decrease even before antineoplastic treatment and sperm banking prior to treatment should be strongly recommended for male cancer patients.

Introduction

According to World Health Organization (WHO) report, infertility will become the third largest disease after tumors and cardiovascular diseases affecting human life and health in the 21st century [1]. Studies have reported that distress about infertility was more prevalent among male survivors of cancer than unaffected men [2–4]. With the increasing number of patients surviving cancer, there is interest in long-term quality of life for cancer patients and reproductive physicians, especially with respect to cancer-related infertility [5, 6]. Therefore, attaches great importance has been placed on studying the potential negative effects of cancer therapies: chemotherapy and radiotherapy, even malignancy itself on fertility [7]. At present, sperm banking before cancer treatment for male cancer patients is considered the most effective method to preserve fertility [8, 9].

In China, a few articles have been published regarding fertility preservation about male cancer patients [10]. There was one report performed a retrospective review of sperm cryopreservation for 143 male cancer patients about the Human Sperm Bank of the National Research Institute for Family Planning in Beijing [11]. Due to its late starting this program in China, man fertility preservation awareness is weak and we need to develop a systemic and patient-centered program for offering cryopreservation to all male cancer patients.

Human Sperm Bank, West China Second University Hospital, Sichuan University, has been offered sperm banking to patients for 10 years. Compare to other sperm banks in China, our unit own relatively more populations in which received 1039 men to cryopreserve sperm for birth demand and cancer patients was 339. In this study, the primary aim of our study was to evaluate semen parameters and the dispositions of the cryopreserved samples among the various types of cancer in our 10-year experience of sperm banking. We simultaneously focused on the reproductive outcomes used cryopreserved semen by ART.

Materials And Methods

Patients

The study was approved by the Ethics Committee of the West China Second University Hospital, Sichuan University. Informed written consent was obtained from all patients prior to their enrollment in this study. In accordance with the guidelines and processes established by our sperm bank, all cancer patients seeking fertility preservation were counseled by an andrology physician and fully informed about the procedure. The information provided included the different methods for fertility preservation, and the procedures for future use of the specimens. All the patients received a physical examination. Medical records of all cancer patients who attempted sperm cryopreservation at Human Sperm Bank, West China Second University Hospital, Sichuan University from January 2010 to December 2019 were reviewed. These data included the following: age at diagnosis, cancer types, pre-and post-cryopreservation semen analysis results, the number of number of straws stored, current banking status, usage of the frozen semen, and the reproductive outcome of using of spermatozoa frozen. The disposition categories were ongoing storage within our unit, discarded, failure to bank, used, and death. The type of cancer was determined by oncologist's letter or histological diagnosis. We followed up cancer patients by telephone.

Semen samples

According to semen quality, we will counsel patients on the number of samples to bank and potential usage of banked samples. The fresh semen and frozen-thawed specimens were analyzed for sperm concentration and motility according to WHO standardized operating process (WHO, 2010). All samples were collected by masturbation. Cryopreservation of the spermatozoa was performed as follows. On the grounds of the semen quality, the cryoprotectant medium was added to semen at a 1:1 or 1:3 medium: sample ratio. Then straws were stored at 4 °C for 15 minutes and then suspended above of liquid nitrogen 5 cm for 10 minutes before being stored in liquid nitrogen. For semen thawing, straws were placed at room temperature for 1 minute and then were transferred to a beaker containing 37°C water until all ice crystals had disappeared. A diagnosis of azoospermia was given by classical analysis of the semen and confirmed by centrifugation of the entire semen sample.
Statistical analysis
The statistical methodology consisted of One-way analysis and Kruskal-Wallis tests. In all cases, \( p < 0.05 \) was considered statistically significant.

Results

Population studied
There were 339 male cancer patients who attempted sperm cryopreservation from January 2010 to December 2019 (Fig. 1A). The cancer diagnoses of the 339 included patients were germ cell tumors (26%), hematological neoplasms (28%), head and neck cancers (19%), thoracic tumors (4%), abdominal tumors (10%), and other tumors (13%) (Fig. 1B). Germ cell tumors included testicular tumors and extragonadal germ cell tumors. Hematological neoplasms included lymphoma and leukemia. The “other” group was composed of skin, sarcoma and peripheral schwannoma. In our unit, we found not only testicular tumors but also extragonadal germ cell tumors had need for fertility preservation. This classification that cancers were devised into six major tumors by body parts was the first showed. The age of patients was 26.7 ± 6.8 years old, among whom 31 patients (9.9%) were adolescents under the age of 18 years.

Semen parameters
Median sexual abstinence was in the range of a minimum of 2 days and a maximum of 7 days [12]. While a few of the patients had a longer period of sexual abstinence than one week, due to emergency treatment (data not shown). The mean semen volume was 3.4 ± 1.5 mL and a median number of straws stored was 4 per patient among different cancer groups. Before cryopreservation, the overall median sperm concentration was 47×10⁶/mL and progressive motility (a + b %) of 49%. Post-thaw analyses after cryopreservation revealed a median concentration of 30×10⁶/mL and motility (a + b %) of 28%. There was no difference in change from pre- to post-thaw motility and recovery rate between the various cancer groups. A statistically significant lower sperm pre- and post-thaw concentration was observed in germ cell tumors compared to the other five cancers (Table 1). When comparing the data of leukemia, lymphoma and testicular cancer group, patients with leukemia had the poorest samples, with lower pre-thaw concentration (Table 2).

| Parameter | Germ cell tumors (n = 81) | Hematological neoplasms (n = 83) | Head and neck cancers (n = 61) | Thoracic tumors (n = 14) | Abdominal tumors (n = 32) | Other Tumors (n = 42) | P-Value² |
|-----------|---------------------------|----------------------------------|-------------------------------|--------------------------|--------------------------|-----------------------|----------|
| volume at banking (mL) | 3.7 ± 1.5 | 3.2 ± 1.3 | 3.3 ± 1.6 | 3.8 ± 1.3 | 2.7 ± 1.3 | 3.5 ± 1.6 | <0.0001 | d |
| numbers of samples banked | 4(1–17) | 4(1–10) | 4(1–20) | 4(2–5) | 4(1–12) | 4(1–8) | 0.5431 | e |
| pre-concentration \( (10^6/mL) \) | 26(0.9–159) | 41(0.7–222) | 64(0.4–620) | 47.5(0.4–108) | 64(3.3–229) | 54.5(1.2–226) | 0.0015 | f |
| pre-motility a + b (%) | 48.5(3.1–83) | 48(1.04-75) | 51.5(4–73) | 53(18–79) | 45(8–70) | 50(9–81) | 0.2334 | d |
| post-concentration \( (10^6/mL) \) | 16.5(0.6–89) | 28(0.5–120) | 42(3.7–193) | 23(0.3–52) | 40(2.2–120) | 37(0.6–148) | 0.0041 | e |
| post-motility a + b (%) | 29(0.66-61) | 29(2–60) | 30.5(8–64) | 23(6–55) | 23(3–45) | 30(0.7–66) | 0.4099 | d |
| Recovery rates (%) | 58.8(2.2–89.6) | 60(9.1–89.6) | 62.4(12.1–89.3) | 52.5(31.9–73.3) | 59(15.2–80.4) | 59.3(2.8–89.2) | 0.8639 | e |

a: mean ± standard deviation
b: median (range)
c: \( p < 0.05 \) significant
d: Comparisons between groups were conducted using One-way analysis.
e: Comparisons between groups were conducted using Kruskal-Wallis tests.
Table 2
Characteristics of testicular tumor, leukemia and lymphoma patients.

| Parameter                              | Testicular tumors (n = 68) | Leukemia (n = 18) | Lymphoma (n = 65) | p-Valuec |
|----------------------------------------|----------------------------|-------------------|-------------------|----------|
| age at banking a                        | 27 ± 7.5                   | 24.7 ± 7.2        | 25.1 ± 5.5        | 0.0115d  |
| volume at banking (mL) a               | 3.8 ± 7.8                  | 2.8 ± 1.3         | 3.4 ± 1.3         | 0.0388d  |
| pre-concentration (10^6/mL) b          | 30 (0.9–159)               | 18.5 (0.7–134)    | 48 (1.5–222)      | 0.0020e  |
| pre-motility a + b (%) b               | 48.5 (3.1–83)              | 41.5 (6.69–48)    | 50 (1.04–73)      | 0.1595d  |
| post-concentration (10^6/mL) b         | 16.4 (0.6–89)              | 10.9 (0.5–92)     | 32 (1–120)        | 0.1436e  |
| post-motility a + b (%) b              | 28 (2.6–61)                | 18.5 (2–37)       | 30 (5–60)         | 0.0563d  |
| Recovery rates (%) b                   | 59.5 (6.8–89.6)            | 53.7 (9.1–77)     | 60.8 (25–89)      | 0.5558e  |

a: mean ± standard deviation
b: median (range)
c: p < 0.05 significant
d: Comparisons between groups were conducted using One-way analysis.
e: Comparisons between groups were conducted using Kruskal-Wallis tests.

Disposition of cryopreserved sperm

We elaborated the cryopreserved sperm states to analyze the further study of improving the utilization. Disposition of cryopreserved sperm categories included ongoing storage (58%), discarded (31%), failure to bank (6%), death (1%) and used (4%) (Fig. 2). Twenty-two patients (6%) failed the sperm cryopreservation due to poor quality (azoospermia, oligoasthenozoospermia, and received chemotherapy). Moreover, we furtherly analyzed the details of men using cryopreserved sperm and their reproductive outcomes. The results showed that leukemia was the most cancers failed cryopreservation (45.5%). We concluded the urgent treatment time for further treatment might be the most reason for this result. The phenomenon needed we communicate with clinicians in a timely manner to ensure leukemia cancers bank sperm before cancer treatment. In the ongoing storage semen, germ cell tumors (29.3%) and hematological neoplasms (26.8%) were the higher proportion (Table 3).

Table 3
Sperm banking outcomes of six types of cancers.

| Parameter     | Germ cell tumors | Hematological neoplasms | Head and neck cancers | Thoracic tumors | Abdominal tumors | Other tumors | Total |
|---------------|------------------|-------------------------|-----------------------|-----------------|-----------------|-------------|-------|
| Ongoing storage | 60 (29.3%)       | 55 (26.8%)              | 37 (18.0%)            | 8 (3.9%)        | 21 (10.2%)      | 24 (11.7%)  | 205   |
| Destroyed     | 22 (20.4%)       | 28 (25.9%)              | 25 (23.1%)            | 6 (5.6%)        | 10 (9.3%)       | 17 (15.7%)  | 108   |
| Used          | 2 (15.4%)        | 4 (30.8%)               | 4 (30.8%)             | 0 (0%)          | 2 (15.4%)       | 1 (7.7%)    | 13    |
| Death         | 0 (0%)           | 2 (50%)                 | 0 (0%)                | 0 (0%)          | 1 (25%)         | 1 (25%)     | 4     |
| Unfrozen      | 5 (22.7%)        | 10 (45.5%)              | 4 (18.2%)             | 0 (0%)          | 1 (4.5%)        | 2 (9.1%)    | 22    |

The outcome of ART with cryopreserved semen

As of December 31, 2019, only 3.8% (13 out of 339) of patients returned to use their cryopreserved semen for ART. Conceptions were achieved in 66.7% (10 out of 15), with 50% (5 out of 10) of pregnancies resulting in delivery, 20% of pregnancies spontaneous abortions (2 out of 10) and 30% (3 out of 10) clinical pregnancies. There were two couples failed concept, and one embryo cryopreservation. The details of these cases are listed in Table 4.
inadequate communication between physician and patients about the risk of post-treatment infertility. In contrast to Europe and the USA, there are no practice guidelines advocating fertility preservation for cancers in China. One obstacle to sperm banking is electively discarded to improve patients' storage time.

We will follow up all cancer who came our cohort for sperm banking for their reproductive outcomes and inquire about the reason why patients selected.

Limitations of our study include inability to follow up patients who were natural conception and not showing the reason patients electively discarded. In future, it is possible that the last recruited patients had too short a follow up time to be evaluated.

Factor that determines the utilization rate. Without this information it is not possible to evaluate the importance of the result. Even if the observation time is 10 years, 3.8% of the patients used their samples in our facility. The time elapsed between sperm freezing and follow up is the fundamental factor that determines the utilization rate.

Frozen semen usage vary between 7–30%, with about 50% of them being successful at in vitro fertilization and intracytoplasmic sperm injection. Cancer patients choose to use their cryopreserved sperm for fertility will result in good chances of fatherhood. Nevertheless, studies report that the rates of pregnancies vary between 7–30%. Specialists in male reproduction or oncologists

Table 4
Details of men using cryopreserved sperm and their reproductive outcomes.

| Diagnosis                  | Age at banking (year) | Number of samples | Raw semen | Frozen-thawed semen | ART       | Reproductive outcome |
|----------------------------|-----------------------|-------------------|-----------|---------------------|-----------|----------------------|
|                            |                       |                   | Volume (mL) | Count (10^6/mL) | Motility (%) | Recovery rates (%)   |
| Testicular tumor           | 27                    | 6                 | 2.6       | 3.4                | 48        | 2.9                  | 31                  | 64.6 | ICSI | live birth | 1         |
| Testicular tumor           | 27                    | 6                 | 6         | 6                  | 49        | 10                   | 22                  | 45   | ICSI | live birth | 1         |
| Leukemia                   | 34                    | 10                | 2.3       | 134                | 48        | 92                   | 37                  | 77   | ICSI | live birth | 1         |
| Leukemia                   | 28                    | 4                 | 3.9       | 9                  | 47        | 3                    | 30                  | 63.8 | ICSI | live birth | 1         |
| Lymphoma                   | 37                    | 8                 | 4.3       | 42                 | 68        | 28                   | 33                  | 48.5 | ICSI/IVF/IUI | no pregnancy | 0        |
| Lymphoma                   | 26                    | 3                 | 3.0       | 31                 | 54        | 20                   | 35                  | 64.8 | ICSI | clinical pregnancies | 0        |
| Nasopharyngeal Carcinoma   | 36                    | 3                 | 2.9       | 80                 | 37        | 64                   | 23                  | 62.2 | IVF  | abortion    | 0         |
| Nasopharyngeal Carcinoma   | 35                    | 5                 | 1.8       | 79                 | 58        | NS                   | NS                  | NS   | IVF  | live birth  | 1         |
| Nasopharyngeal Carcinoma   | 41                    | 4                 | 3.1       | 108                | 52        | NS                   | NS                  | NS   | IVF  | no pregnancy | 0         |
| Thyroid tumor              | 32                    | 4                 | 3.6       | 78                 | 42        | 66                   | 23                  | 54.8 | IVF  | abortion    | 0         |
| Colorectal cancer          | 46                    | 4                 | 1.6       | 56                 | 39        | 43                   | 23                  | 59   | ICSI | embryo cryopreservation | 0        |
| Gastric cancer             | 41                    | 3                 | 1.8       | 93                 | 46        | 40                   | 25                  | 54.3 | ICSI | clinical pregnancies | 0        |
| Hemangiosarcoma            | 28                    | 6                 | 2.5       | 26                 | 28        | 16                   | 11                  | 39.3 | ICSI | clinical pregnancies | 0        |
| Abbreviations: ART, assisted reproduction technology; ICSI, intracytoplasmic sperm injection; IVF, In vitro fertilization; IUI, intrauterine insemination. |

Reproductive outcomes of 13 patients who used their banked samples for 15 assisted reproductive cycles.

Discussion

As cancer survival rates improve, more attention is being directed from issues of cancer treatment toward enhancing quality-of-life issues related to long-term survivorship for cancer patients. Cryopreservation of semen samples is a noninvasive procedure and is the main option for male cancer patients [13].

In our study, we demonstrating that male cancer patients in the Sichuan, China, use sperm banking for fertility preservation. During the 10 years of our study, there were 339 male cancer patients attempted to conduct fertility preservation, the most population at present reported in China. To our knowledge, this is the first report demonstrating that sperm parameters of different cancers types according to body regions. We divide into six portions: germ cell tumors, hematological neoplasms, head and neck cancers, thoracic cancers, abdominal tumors and other tumors. We found that men with germ cell tumors (including testicular cancer and extragonadal germ cell tumor) had an inferior pre-and post-concentration compared with men with other types of cancer. However, when we separately compared testicular cancer, leukemia, and lymphoma we found that leukemia showed the lowest sperm concentration among them. Although there were reported that sperm count and motility was significantly lower in testicular tumors in some prior studies [14–17]. There are several causes of semen quality decline before cancer treatment, such as disruption of the blood-testis barrier and endocrine derangements [18, 19]. Some studies show that cancer patients especially leukemia patients have an innate suppression of spermatogenesis, but the mechanism for suppression is under studied [15, 20, 21]. So, not so paradoxically, testicular tumors needing removing one testicle and blood tumor (including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and leukemia) causing fever both resulted in lower sperm concentrations than other cancers.

Cancer patients choose to use their cryopreserved sperm for fertility will result in good chances of fatherhood. Nevertheless, studies report that the rates of frozen semen usage vary between 7–30%, with about 50% of them being successful at in vitro fertilization and intracytoplasmic sperm injection [22, 23]. Over the course of 10 years, 3.8% of the patients used their samples in our facility. The time elapsed between sperm freezing and follow up is the fundamental factor that determines the utilization rate. Without this information it is not possible to evaluate the importance of the result. Even if the observation time is 10 years, it is possible that the last recruited patients had too short a follow up time to be evaluated.

Limitations of our study include inability to follow up patients who were natural conception and not showing the reason patients electively discarded. In future, we will follow up all cancer who came our cohort for sperm banking for their reproductive outcomes and inquire about the reason why patients selected electively discarded to improve patients’ storage time.

In contrast to Europe and the USA, there are no practice guidelines advocating fertility preservation for cancers in China. One obstacle to sperm banking is inadequate communication between physician and patients about the risk of post-treatment infertility [24]. Specialists in male reproduction or oncologists
should be discussed with cancer patients about sperm preservation as early as possible. All ways of oncological therapy, including surgical procedures, chemotherapy and radiotherapy have some risk to fertility [4]. We are all talking about adults that can cryopreserve sperm by masturbation. To date, for the prepubertal male patients especially the patients that cannot masturbate to obtain sperm, cryopreservation of sperm is impossible. When it is not possible to obtain sperm, testicular tissue containing spermatogonia stem cells (SSCs) can be obtained by biopsy. Exciting basic science work is under way that addresses the unmet fertility preservation and may expand fertility options for men in the future.

Conclusion
In conclusion, our study supports studies that sperm banking is an effective way of fertility preservation in cancer patients. Fertility preservation utilization is very low among Chinese male cancer patients. Therefore, reproductive physicians and oncologists are required to discuss fertility preservation before gonadotoxic therapy with all male cancer patients. Sperm cryopreservation is a quick and effective technique that can preserve fertility. Development of local clinical guidelines and the organization of conference to promote the fertility preservation should be encouraged.

Abbreviations
ART: assisted reproductive treatments; WHO: World Health Organization; SSCs: spermatogonia stem cells; EGTC, extragonadal germ cell tumors; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, Chronic myelocytic leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; NPC, nasopharyngeal carcinoma; ICSI, intracytoplasmic sperm injection; IVF, In vitro fertilization; IUI, intrauterine insemination.

Declarations
Acknowledgements
Not applicable.

Author Contributions
Xiao Liu wrote the article and prepared the tables and figures. Bo Liu, Xiao Xiao, Li Wang, Xiaofang Zhu and Bizhen Shu verified all data collected. Wenrui Zhao carried out the data analysis. Xiao Liu, Bo Liu, Shasha Liu and Yang Xian freezed semen. Min Jiang and Bin Zhou provide technical support. Fuping Li designed the study and edited the article. All authors read and approved the final manuscript.

Funding
This study was supported by Sichuan Science and Technology Program (No. 2020ZYD007).

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the West China Second University Hospital, Sichuan University. Informed written consent was obtained from all patients prior to their enrollment in this study.

Conflict of Interest
The authors declare that they have no competing interest.

References
1. Rostami Dovom M, Ramezani Tehrani F, Abedini M, Amirshekari G, Hashemi S, Noroozzadeh M. A population-based study on infertility and its influencing factors in four selected provinces in Iran (2008–2010). Iran J Reprod Med. 2014;12:561–6.
2. Williams DH, Karpman E, Sander JC, Spiess PE, Pisters LL, Lipshultz LI. Pretreatment semen parameters in men with cancer. J Urol. 2009;181:736–40.
3. Bahadur G, Ozturk O, Muneer A, Wafa R, Ashraf A, Jaman N, Patel S, Oyede AW, Ralph DJ. Semen quality before and after gonadotoxic treatment. Hum Reprod. 2005;20:774–81.
4. Barak S. Fertility preservation in male patients with cancer. Best Pract Res Clin Obstet Gynaecol. 2019;55:59–66.
5. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 2005;6:209–18.
6. Moss JL, Choi AW, Fitzgerald Keeter MK, Brannigan RE. Male adolescent fertility preservation. Fertil Steril. 2016;105:267–73.
7. Katz DJ, Kolon TF, Feldman DR, Mulhall JP. Fertility preservation strategies for male patients with cancer. Nat Rev Urol. 2013;10:463–72.
8. Holoch P, Wald M. Current options for preservation of fertility in the male. Fertil Steril. 2011;96:286–90.
9. Jahnukainen K, Ehmske J, Hou M, Schlatt S. Testicular function and fertility preservation in male cancer patients. Best Pract Res Clin Endocrinol Metab. 2011;25:287–302.
10. Fu LL, Zhang KS, Gu YQ. [Fertility preservation for male adolescent cancer patients]. Zhonghua Nan Ke Xue. 2017;23:262–6.

11. Fu L, Zhou F, An Q, Zhang K, Wang X, Xu J, Guo Y, Lu W, Liang X, Gu Y. Sperm Cryopreservation for Male Cancer Patients: More than 10 Years of Experience, in Beijing China. Med Sci Monit. 2019;25:3256–61.

12. Lu JC, Huang YF, Lu NJ. [WHO Laboratory Manual for the Examination and Processing of Human Semen: its applicability to andrology laboratories in China]. Zhonghua Nan Ke Xue. 2010;16:867–71.

13. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, Wallace WH, Wang ET, Loren AW. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36:1994–2001.

14. Chung K, Irani J, Knee G, Efymow B, Blasco L, Patrizio P. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obstet Gynecol Reprod Biol. 2004;113(Suppl 1):7–11.

15. Bonetti TC, Pasqualotto FF, Queiroz P, Iaconelli A Jr, Borges E Jr. Sperm banking for male cancer patients: social and semen profiles. Int Braz J Urol 2009, 35:190–197; discussion 197–198.

16. Menon S, Rives N, Mousset-Simeon N, Sibert L, Vannier JP, Mazurier S, Masse L, Duchesne V, Mace B. Fertility preservation in adolescent males: experience over 22 years at Rouen University Hospital. Hum Reprod 2009, 24:37–44.

17. Johnson MD, Cooper AR, Jungheim ES, Lantzendorf SE, Odem RR, Ratts VS. Sperm banking for fertility preservation: a 20-year experience. Eur J Obstet Gynecol Reprod Biol. 2013;170:177–82.

18. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005:12–17.

19. Totaling JM, Lopushnyan NA, Davenport M, Christensen H, Pagel ER, Muller CH, Walsh TJ. Raw and test-thaw semen parameters after cryopreservation among men with newly diagnosed cancer. Fertil Steril. 2013;99:464–9.

20. Botchan A, Hauser R, Gamzu R, Yogev L, Lessing JB, Paz G, Yavetz H. Sperm quality in Hodgkin’s disease versus non-Hodgkin’s lymphoma. Hum Reprod. 1997;12:73–6.

21. Moody JA, Ahmed K, Yap T, Minhas S, Shabbir M. Fertility management in testicular cancer: the need to establish a standardized and evidence-based patient-centric pathway. BJU Int. 2019;123:160–72.

22. van Casteren NJ, van Santbrink EJ, van Inzen W, Romijn JC, Dohle GR. Use rate and assisted reproduction technologies outcome of cryopreserved semen from 629 cancer patients. Fertil Steril. 2008;90:2245–50.

23. Neal MS, Nagel K, Duckworth J, Bissessar H, Fischer MA, Portwine C, Tozer R, Barr RD. Effectiveness of sperm banking in adolescents and young adults with cancer: a regional experience. Cancer. 2007;110:1125–9.

24. Achille MA, Rosberger Z, Robitaille R, Lebel S, Gouin JP, Bulitz BD, Chan PT. Facilitators and obstacles to sperm banking in young men receiving gonadotoxic chemotherapy for cancer: the perspective of survivors and health care professionals. Hum Reprod. 2006;21:3206–16.

Figures
**Figure 1.** Flow diagram of cancer men who presented to Sichuan human sperm bank from 2010 to 2019 for sperm cryopreservation. Abbreviations: EGTC, extragonadal germ cell tumors; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, Chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; NPC, nasopharyngeal carcinoma.

**Figure 1**

Flow diagram

**Figure 2.** Outcomes for the cancer patients who attempted banking

- Ongoing storage (n=205)
- Failed to bank a sample (n=22)
- Electively discarded (n=108)
- Death (n=4)
- Used for fertility treatments (n=13)